OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients
OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients
Recruiting · NCT07406217 · Registry updated 2026-02-18Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients | COVID-19, Coronaviridae Infections, Infections, Nidovirales infectious disease, Orthocoronavirinae infectious disease, RNA Virus Infections, immune system disorder, immunodeficiency disease, inborn error of immunity, lung disorder, pneumonia, respiratory system disorder, respiratory tract infectious disorder, viral infectious disease, viral pneumonia | Recruiting | Phase 2 | 2026-02-18 | NCT07406217 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| ANRS, Emerging Infectious Diseases | 47 |
| Calmy Alexandra | 2 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Basel University Hospital | Basel | Switzerland | 1 |
| CHUV | Lausanne | Switzerland | 1 |
| Hôpitaux Universitaires de Genève | Geneva | Switzerland | 6 |
| University Hospital Zurich | Zurich | Switzerland | 43 |